Stock Taper 
BHC
$6.32
▲ UP 0.32% (0.02)
KEY STATISTICS
Market Cap$2.36 B
52w High$8.00
52w Low$4.33
Dividend Yield4.99%
FrequencyQuarterly
P/E1.61
Volume1.36M
Shares Out.373.99M
COMPANY
LEADERSHIP
CHIEF EXECUTIVE
Thomas J. Appio
COMPENSATION 2026
Salary$1,236,000
Stock Awards$13,032,562
Incentive Plan Pay$2,336,000
All Other Comp.$22,764
Total$16,877,326
ABOUT
SECTOR
Healthcare
WENT PUBLIC
March 29, 1994
METHOD OF GOING PUBLIC
Reverse Merger
FULL TIME EMPLOYEES
20,300
PRICE TARGET
Target High$16.00
Target Low$8.00
Target Median$8.50
Target Consensus$9.83
UPCOMING EARNINGS
DateOct 28, 2026
DayWednesday
Rev. Est.$2.78B
OCT
28
WED
SPLIT RECORD
| DATE | TYPE | RATIO |
|---|---|---|
| 2000-10-16 | Forward | 2:1 |
| 2000-10-05 | Forward | 2:1 |
| 2000-01-20 | Reverse | 1:1 |
| 2000-01-10 | Forward | 2:1 |
| 1996-01-17 | Reverse | 1:1 |
| 1996-01-08 | Forward | 3:1 |
PRICE
$6.32 ▲ UP 0.32% (+$0.02)About Bausch Health Companies Inc.
https://www.bauschhealth.com ↗Bausch Health Companies Inc. develops, manufactures, and markets pharmaceutical, medical device, and OTC products across eye health, gastroenterology, and dermatology through five segments worldwide.
INDUSTRY
Drug Manufacturers - Specialty & Generic
A PRODUCT BAUSCH HEALTH COMPANIES INC. IS KNOWN FOR
Xifaxan (rifaximin)
Xifaxan, Bausch Health's top-selling antibiotic for IBS-D and hepatic encephalopathy, is a key revenue driver, but recent clinical trial setbacks have impacted its stock and growth outlook.
Revenue by Products
| Icon | PRODUCT | Q2-2025 | Q3-2025 | Q4-2025 | Q2-2026 |
|---|---|---|---|---|---|
 | Product | $2.5B | $2.66B ▲ | $2.77B ▲ | $2.83B ▲ |
 | Product and Service Other | $26M | $24M ▼ | $28M ▲ | $27M ▼ |
Revenue by Geography
| Map | REGION | Q1-2024 | Q2-2024 | Q3-2024 | Q4-2024 |
|---|---|---|---|---|---|
 | United States and Puerto Rico | $1.25B | $1.44B ▲ | $1.53B ▲ | $1.54B ▲ |
 | Other Countries | $256M | $272M ▲ | $263M ▼ | $292M ▲ |
 | CHINA | $97M | $122M ▲ | $132M ▲ | $145M ▲ |
 | CANADA | $90M | $99M ▲ | $104M ▲ | $109M ▲ |
 | POLAND | $86M | $78M ▼ | $92M ▲ | $94M ▲ |
 | MEXICO | $76M | $84M ▲ | $88M ▲ | $67M ▼ |
 | FRANCE | $61M | $65M ▲ | $52M ▼ | $52M |
 | JAPAN | $43M | $47M ▲ | $46M ▼ | $52M ▲ |
 | KOREA REPUBLIC OF | $30M | $34M ▲ | $38M ▲ | $44M ▲ |
 | GERMANY | $44M | $41M ▼ | $40M ▼ | $34M ▼ |
 | SPAIN | $23M | $27M ▲ | $21M ▼ | $28M ▲ |
 | ITALY | $24M | $24M | $23M ▼ | $23M |
ETFS HOLDING THIS STOCK
ETFS HOLDING
13
LISTED HERE
7
RANKED BY POSITION SIZE
INSTITUTIONAL OWNERSHIP
SHARES OWNED
52.57%
HOLDERS
359
TOP 12 OF 359 · RANKED BY POSITION SIZE
Paulson & Co. Inc.
Goldentree Asset Management LP
Nomura Holdings Inc
Healthcare Of Ontario Pension Plan Trust Fund
Vanguard Group Inc
Royal Bank Of Canada
National Bank Of Canada /Fi/
Goldman Sachs Group Inc
Mfn Partners Management, LP
Sg Americas Securities, LLC
Acadian Asset Management LLC
Kohlberg Kravis Roberts & Co. L.P.
RATINGS SNAPSHOT
Overall rating: B-
Discounted Cash Flow5
Return On Equity5
Return On Assets1
Debt To Equity1
Price To Earnings1
Price To Book1
Overall Score2
TRADES BY CONGRESS
HOUSE TRADES
Susie Lee
Sale (Full)
2020-08-27
INSIDER TRADES
★
OFFICER: PRESIDENT, US PHARMA
Lenar Aimee J.
Sale · 36.8K shares
2026-08-19
★
OFFICER: PRESIDENT, US PHARMA
Lenar Aimee J.
Sale · 5.3K shares
2026-07-17
★
OFFICER: PRESIDENT, US PHARMA
Lenar Aimee J.
Sale · 23.4K shares
2026-07-15
★
OFFICER: SVP, CONTROLLER & CAO
LEE STEVEN HYOSIG
Sale · 3.1K shares
2026-07-14
MOST RECENT ANALYST GRADES
GRADE SUMMARY
SECTOR PERFORM 1
EQUAL WEIGHT 1
HOLD 1
3 GRADES IN THE LAST 12 MONTHS
SECTORS PEERS
| PEER | PRICE | |
|---|---|---|
 HAE | $103.96 | COMPARE |
 CON | $34.26 | COMPARE |
 BEAM | $29.32 | COMPARE |
 MLYS | $25.60 | COMPARE |
 XRAY | $11.12 | COMPARE |
 HCM | $12.38 | COMPARE |
 PRGO | $14.48 | COMPARE |
 ALVO | $4.95 | COMPARE |